Lung Cancer Conference 2020: A Time of Hope in Lung Cancer 19 - 21 February, 2020 Melbourne Convention and Exhibition Centre
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
8 Australian th
Lung Cancer
Conference 2020:
A Time of Hope in Lung Cancer
19 - 21 February, 2020
Melbourne Convention and Exhibition Centre
In collaboration with: Endorsed by: Proudly sponsored by:
Platinum Gold Silver
Welcome from
Lung Foundation Australia
Welcome delegates of the 8th Biennial Australian mental health issues faced by Australians living with
Lung Cancer Conference (ALCC). lung cancer. In 2020, the ALCC features multiple
plenary sessions and offers delegates the opportunity
In 2020, Lung Foundation Australia celebrates 30
to shape a unique learning experience through diverse
years of service and support to Australians living
concurrent sessions, ALTG member meetings, sponsor
with and impacted by lung disease and lung cancer.
symposiums, and an exciting combination of evolutions
We acknowledge all those that have contributed to
in lung cancer treatment, technology, research and
making the last 30 years a tremendous success, and
models of care. In another first, the program has been
most importantly we look forward with optimism to a
endorsed by the International Association for the
brighter future, particularly for families whose lives have
Study of Lung Cancer (IASLC).
been forever changed by a lung cancer diagnosis.
On behalf of Lung Foundation Australia, I would like to
As Chairperson of Lung Foundation Australia, I warmly
acknowledge and thank our event partners for their
welcome you to Melbourne, Australia and thank you for
generous sponsorship; without such support ALCC
participating in the ALCC 2020. For the first time, the
could not take place. Thank you also to the Conference
conference has joined with the Australasian Lung Cancer
Convenors Prof Kwun Fong and A/Prof Thomas John, the
Trials Group Annual Scientific Meeting (ALTG-ASM)
Conference Organising Committee and Lung Foundation
and will deliver a comprehensive three-day program
Australia staff for their efforts in shaping what will be
to uniquely engage and unite lung cancer health
an excellent event.
professionals, consumer advocates and researchers from
across Australia. We hope you enjoy the ALCC 2020 and take the time
to share with us your expertise and experience so we
The ALCC program represents the shared strategic
may continue to improve the lives of patients and
objectives of Lung Foundation Australia, the Australia
families impacted by lung cancer and generate the
& New Zealand Lung Cancer Nurses Forum (ANZ-LCNF)
translational evidence required for improvements in
and the ALTG. Together with ALTG, Lung Foundation
everyday clinical practice.
Australia seeks to design and conduct clinical trials
which contribute meaningfully to the evidence base for
high quality lung cancer diagnosis, treatment and long-
Yours sincerely,
term monitoring. As outlined in our lung cancer report,
‘Making Lung Cancer A Fair Fight: A Blueprint for Reform’,
our current key advocacy priorities include:
• Improving the quality of care for patients by
increasing the number of lung cancer nurses. Prof Christine Jenkins AM
Chairperson
• Implementing a targeted national lung cancer
Lung Foundation Australia
screening program.
• Increasing research funding for lung cancer
commensurate to the burden of disease.
These initiatives have inspired the conference theme
2020: A Time of Hope in Lung Cancer. The scientific
program seeks to highlight the social, economic and
2 Australian Lung Cancer Conference 2020 Handbook
Contents
Welcome from Lung Foundation Australia 2
Code of Conduct 4
Welcome from the Conference Co-Convenors 5
Meet the ALCC 2020 Local Organising Committee 6
International and Sponsored Speakers 7
Delegate and Speaker Information 11
Program
Wednesday 19 February 13
Thursday 20 February 14
Friday 21 February 16
Welcome from the Australia and New Zealand
Lung Cancer Nurses Forum (ANZ-LCNF) Chair 18
ANZ-LCNF Workshop Program 19
Faculty of Radiation Oncology Lung Interest
Cooperative (FROLIC) Workshop Program 22
Abstracts: Poster Listing 24
Abstracts: Oral Presentations 26
How you can support us? 27
3 Australian Lung Cancer Conference 2020 Handbook
Acknowledgement of Country
Lung Foundation Australia respectfully acknowledges the Boon Wurrung and Woiwurrung (Wurundjeri) peoples of
the Kulin Nation as the Traditional Owners of the land upon which the Australian Lung Cancer Conference 2020 is
being held. The Melbourne Convention and Exhibition Centre is built on their ancestral lands and we pay our respects
to them, and to their elders, past, present and emerging.
Code of Conduct
The Local Organising Committee of ALCC 2020 welcomes all delegates to the conference, including
consumer advocates. Whilst we are all united in the vision to improve outcomes for those affected by
lung cancer, it is important to note that we come from varied backgrounds with unique experiences.
To ensure that all delegates can make the most of the learning opportunities provided, in a safe
and respectful environment, we ask you to please read and observe the following throughout your
conference experience.
• We support and encourage consumer advocates to participate in the conference program and their
right to be heard and respected. Consumer advocates are permitted to ask questions in allocated
question times and enter the exhibition area when wearing their conference lanyard.
• A dedicated Consumer Advocates Lounge will be open (Room 101) throughout the course of the
conference. This area will be a quite space where refreshments will be available for consumer
delegates and approved users only.
• The program is designed to increase understanding of the advances in lung cancer research,
treatment and care. When considering your questions to speakers, please note some of the tests
and/or treatments presented may not yet be available in Australia.
• Health professionals, researchers and pharmaceutical representatives are unable to provide consumer
advocates with individualised advice on medical conditions or any aspect of treatment.
• We are committed to providing a conference environment in accordance with the Medicines Australia
Code of Conduct and specifically ask that all delegates and exhibitors are aware that individual
promotion of products to the general public is in breach of the Code.
4 Australian Lung Cancer Conference 2020 Handbook
Welcome from
the Conference
Co-Convenors
On behalf of Lung Foundation Australia, it gives us Forum (ANZ-LCNF) Nursing and Allied Health
enormous pleasure to welcome you to Melbourne Workshop and the Faculty of Radiation Oncology
and to thank you for participating in the 8th Lung Interest Cooperative (FROLIC) workshop. We
Biennual Australian Lung Cancer Conference (ALCC). are delighted to welcome delegates from across
Australia, New Zealand and the international
For the first time the ALCC and the Australasian
representatives, who collectively provide valuable
Lung Cancer Trials Group Annual Scientific
insight into local and international advances in
Meeting (ALTG-ASM) have joined forces to deliver
lung cancer. We thank you for attending and for
a comprehensive program which will no doubt
the significant support provided by sponsors
uniquely engage and unite lung cancer health
and exhibitors. Please take the time to visit our
professionals, consumers and researchers. We are
exhibitors during the designated breaks. We hope
delighted that the event has been endorsed by the
you enjoy the meeting and share with us your
International Association for the Study of Lung
expertise and experience so we can continue to
Cancer (IASLC).
improve outcomes for lung cancer and generate
The ALCC 2020 conference program represents the evidence required for improvements in clinical
the strategic objectives of both Lung Foundation practice.
Australia and ALTG. Lung Foundation Australia’s
current key advocacy efforts include improving Yours sincerely,
access to treatment and lung cancer nurses,
implementing a national lung cancer screening
program and funding of lung cancer research
commensurate with the burden of disease. These
initiatives, as outlined in ‘Making Lung Cancer A Fair
Fight: A Blueprint for Reform’, inspire the theme
of ALCC 2020. The report addresses the social,
economic and mental health issues of Australians
living with lung cancer. Together, with initiatives by
ALTG to design and conduct trials which contribute
to evidence for high quality diagnosis, treatment
and monitoring of lung cancer, we strive to effect
change in the health and wellbeing outcomes of
Professor Kwun Fong Associate Professor
lung cancer patients.
Co-Chair, Local Thomas John
The ALCC 2020 program is an exciting combination Organising Committee Co-Chair, Local
of evolutions in treatment, technology, research Organising Committee
and supportive care. The conference will feature
oral and poster sessions, sponsored symposiums
and ALTG member meetings. The pre-conference
events include Australia New Zealand Lung Cancer
5 Australian Lung Cancer Conference 2020 Handbook
Meet the
Local Organising Committee
Professor Kwun Fong Dr Ashanya Malalasekera
Thoracic and Sleep Physician at The Prince Charles Medical Oncologist and Senior Lecturer at the
Hospital and Professor with the University of University of Sydney.
Queensland School of Medicine.
Associate Professor Rob Stirling
Associate Professor Thomas John Respiratory Specialist at The Alfred Hospital,
Medical Oncologist at the Peter MacCallum Melbourne and Chairman of the Lung Cancer
Hospital in Melbourne. Multidisciplinary Team.
Professor Fraser Brims Dr Jaclyn Yoong
Consultant Respiratory Physician and Head of Palliative Care Physician and Medical Oncologist at
Department Sir Charles Gairdner Hospital. Northern Health and Monash Health.
Dr Vanessa Brunelli Dr Lisa Briggs
Research Fellow at Queensland University of - Consumer Advocate and 5-year Stage IV lung
Technology and Nurse Researcher at Princess cancer survivor
Alexandra Hospital. - Passionate about improving the visibility of lung
cancer in Australia
Mary Duffy, RGN/RSCN, RSM
Graduate Diploma of Advanced Nursing in - Wife and Mum
Oncology and Palliative care. Master of Philosophy - Victorian Finalist - 2020 Australian of the Year
by Nursing Research. ‘Local Hero’ category
- Member, Lung Cancer Patient Advisory
Dr Lara Edbrooke Committee, Lung Foundation Australia
Grade 4 Allied Health Researcher and
Physiotherapist at Peter MacCallum Hospital. Tom Wood
- Consumer Advocate
Dr Kerry Hancock
- Passionate about equity, technology and news
General Practitioner and Principal, Chandlers
Hill Surgery, Happy Valley SA. - Son, Brother and Carer
- Member, Lung Cancer Patient Advisory
Associate Professor Gerry Hanna Committee, Lung Foundation Australia
Director of Radiation Oncology at the Peter
MacCallum Cancer Centre, Melbourne.
Associate Professor
Marie-Liesse Asselin-Labat
Joint-Head of the Personalised Oncology Division
at the Walter and Eliza Hall Institute of Medical
Research in Melbourne.
6 Australian Lung Cancer Conference 2020 Handbook
International and
Sponsored Speakers
Professor Michael Boyer AM
Professor Michael Boyer is a Medical Oncologist and the Chief Clinical Officer at Chris
O’Brien Lifehouse. He is a Conjoint Professor of Medical Oncology (Thoracic Oncology)
at the University of Sydney and Director of the Sydney Catalyst Translational Cancer
Research Centre.
Professor Boyer has over 25 years of experience in the management of thoracic
malignancies and head and neck cancers. His main research interest is in clinical trials of new agents in
the management of lung cancer, mesothelioma and head and neck cancers. He is the author of over 170
publications, has given numerous national and international presentations, both invited and selected from
abstract submission, and is actively involved in the lung cancer community.
Dr Federico Cappuzzo MD
Dr Federico Cappuzzo has been the Director of Medical Oncology at AUSL della
Romagna-Ravenna since April 2016 and in January 2017 he became the Director on
Hematology and Oncology Department.
Dr Cappuzzo is a member of the Italian Association in Medical Oncology, European
Society for Medical Oncology, American Society Clinical Oncology and International
Association for the Study of Lung Cancer (IASLC) and since 2006 as a Member of the editorial board of
Lung Cancer.
In January of 2016, he became the Chairman of the Educational Committee of IASLC. In 2006, 2009 and
2012 he received research grants from the Italian Association for Cancer Research on targeted therapies
in lung cancer and is the author of more than 200 papers in peer-review journals, mainly in translational
research in lung cancer.
Dr Marina Chiara Garassino
Dr Marina Chiara Garassino is the Chief of the Thoracic Oncology Unit at the
prestigious Istituto Nazionale dei Tumori cancer institute in Milan, Italy.
She leads the strategy for clinical and translational research in advanced and locally
advanced non-small cell lung cancer, small-cell lung cancer, mesothelioma and
thymic malignancies.
Dr Garassino's main research interests include; the development of new drugs, therapeutic strategies and
biomarkers. Dr Garassino has contributed to over 120 peer-reviewed publications, including credits as first or
last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Annals
of Oncology. Dr Garassino has delivered many presentations at international conferences including American
Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), European CanCer
Organisation, European Society of Medical Oncology (ESMO), World Conference on Lung Cancer (WCLC).
Dr Garassino is currently serving as ESMO Council Chair of the National Societies Committee and serves on
several ESMO Committees (Public Policy extended Committee, Press Committee, Women for Oncology
Committee, Lung Cancer faculty, Membership Committee).
Dr Garassino is working on both ESMO, WCLC and ASCO annual congress Lung Cancer Track (2019). Dr
Garassino is the founder and president of Women for Oncology Italy.
7 Australian Lung Cancer Conference 2020 Handbook
Professor Nir Peled MD PhD
Professor Nir Peled is Head of the Oncology Division at the Legacy Heritage
Oncology Center and Dr Larry Norton Institute at Soroka Medical Center, Ben-
Gurion University, Beer Sheva, Israel. He is board certified in internal medicine,
pulmonology, and medical oncology.
An expert in thoracic oncology, Professor Peled is a Board Member at the
International Association for the Study of Lung Cancer (IASLC) and the past Chair of the Thoracic Cancer
Assembly of the European Thoracic Society and the past Chair of the Screening Committee of the
International Association of Lung Cancer.
Professor Peled’s research focuses on the wide translational and clinical perspectives of lung cancer,
including personalised targeted therapy, immunotherapy, cancer evolution, biomarker development, and
early detection of this disease. He has published nearly 200 peer-reviewed articles, including guidelines on
the early diagnosis of lung cancer, biomarker development, and treatment of advanced disease. Professor
Peled is on the editorial board of numerous journals, including the Journal of Thoracic Oncology and other
lung-cancer related publications. In October 2019 he became a board member of the IASLC and member of its
financial committee.
Professor Angela Mary Tod
Professor of Older People and Care, Division of Nursing and Midwifery at the
University of Sheffield.
For the last 20 years Professor Tod has worked in research with a particular focus
in lung cancer and mesothelioma patient experience studies. Professor Todd
established and chaired the Lung Cancer Nursing UK Research Interest Group with a
portfolio of research projects in collaboration with Mesothelioma UK.
Professor Tod is also a Joint Principle Investigator on a National Strategic Research Alliance between the
University of Sheffield and the Royal College of Nursing in the UK. This alliance incorporates a programme of
work on new and emerging nursing roles including advanced and specialist nursing.
A/Prof Nick Pavlakis
A/Prof Nick Pavlakis is a senior staff specialist in the Department of Medical Oncology
at Royal North Shore Hospital and conjoint Associate Professor in the Faculty of
Medicine University of Sydney. He is currently Clinical Services and Trials Director of
the Northern Cancer Institute at St Leonards, President of the Australasian Lung
Cancer Trials Group (ALTG) and President of the Clinical Oncologic Society of Australia
(COSA). His background includes a PhD in anti-angiogenic cancer drug development and a Masters of
Clinical Epidemiology, University of Sydney. He has extensive experience in clinical research as clinical lead
or site Primary Investigator in national and international clinical trials in lung cancer, mesothelioma and
gastrointestinal cancers, as well as translating evidence into practice with lung cancer systematic reviews
and guideline development.
8 Australian Lung Cancer Conference 2020 Handbook
A/Prof Trishe Leong
A/Prof Trishe Leong is the Medical Director of Pathology and Director of Anatomical
Pathology at Austin Health, Melbourne, where she has been involved in the
supervision and reporting of diagnostic molecular testing for solid tumours since
2015. She received her undergraduate medical degree from the University of Adelaide
and trained in Anatomical Pathology in Melbourne, being admitted to Fellowship in
2006. Following this she worked at Monash Medical Centre and the Victorian Cytology Service, where she
was Deputy Managing Pathologist, before joining Austin Health in 2010. She previously served from 2015-
2018 as the Honorary Treasurer of the Australasian Division of the International Academy of Pathologists,
followed by a term as Divisional Vice President, and is the current Secretary/Treasurer of the Royal College
of Pathologists Australasia.
9 Australian Lung Cancer Conference 2020 Handbook
Please take time to Thank you to our generous event sponsors
visit the exhibition Platinum
and engage with our
event sponsors.
Download the myINTERACT app to
collect points and win prizes!
Trade Displays Gold
• Becton Dickinson
• Roche Foundation Medicine
• Takeda
• Maurice Blackburn Lawyers
Silver
• Healthinc
• Cancer Council Victoria
• Victorian Tumour Summits
See you at the ALCC 2020 Dinner!
Thursday 20 February 2020
Join us for dinner and live entertainment as we announce
and celebrate the recipients of the Lung Foundation
Australia Lung Cancer Research Awards for 2020.
Welcome drinks from
7:00pm for 7:30pm commencement.
Places are limited and registration
is required to attend. Visit
events.ozaccom.com.au
to register.
10 Australian Lung Cancer Conference 2020 HandbookDelegate and
Speaker Information
Registration desk hours MCEC Free Wifi
Registration desk is located on Level 1, open from: Free WIFI is available at the conference.
To connect to WIFI, select the MCEC Free
Wednesday 19 February: 7:30am – 4:30pm
WIFI Network, no password is required.
Thursday 20 February: 6:30am – 4:30pm
Friday 21 February: 6:30am – 2:00pm
Conference Catering
All conference catering will be served in the exhibition
Speaker Preparation Room area. Delegates who have advised special dietary
requirements will have access to a separate buffet
The speaker preparation room is located on Level 1, which will be supervised by an events staff member
Room 107 and is open: for your convenience. If you are attending a catered
sponsor symposium, please arrive early to collect
Thursday 20 February: 6:30am – 5:00pm
your meal.
Friday 21 February: 6:30am – 4:00pm
Evaluation
Social Media Your opinion is important to us! A post-event survey
The official conference social media channels are: will be available from morning tea on Friday 21
February via the conference app. Please take the time
Twitter: @Lungfoundation
to complete the evaluation to help us improve future
Facebook: @Lungfoundation ALCC events. After completing the evaluation, you
Instagram: @Lungfoundation will have access to the speaker presentations.
LinkedIn: Lung Foundation Australia
Consumer Advocates Lounge
Hashtag #ALCC2020 and tag us social media.
The dedicated consumer advocates lounge is
located in Room 101 and is accessible throughout the
Event Coordinator conference by consumer advocate delegates only.
Lisa Cunningham, Senior Event Manager,
Medical Meetings Conference App
Contact number: 0435 569 096 Download the myINTERACT app to:
Email: lisa@medicalmeetings.com.au - View the ALCC program, abstracts and exhibitor
Should you require assistance or have questions details
throughout the event please speak with a member - Complete session evaluations
of the Medical Meetings team. - Engage with exhibitors and win great prizes
- Snap and upload the best conference photo to win
movie passes.
Poster Display
myINTERACT
Posters will be on display throughout the duration
is available on
of ALCC 2020 in Room 104 and oral presentations
iPhone, Android,
will take place during morning tea and lunch
breaks. Please take time to view the posters over a Tablet and Desktop.
complimentary coffee, kindly provided by MSD.
11 Australian Lung Cancer Conference 2020 HandbookTogether. Today and Tomorrow
Lung cancer patients in mind
People, products and services working together to support
you and your patients with lung cancer
atezolizumab
atezolizumab bevacizumab
bevacizumab alectinib 150
alectinib 150 mg
mg capsules
capsules erlotinib
erlotinib
Please review the Product Information for TECENTRIQ (www.roche-australia.com/productinfo/tecentriq),
AVASTIN (www.roche-australia.com/productinfo/avastin), ALECENSA (www.roche-australia.com/
productinfo/alecensa) and TARCEVA (www.roche-australia.com/productinfo/tarceva) before prescribing,
available on request from Roche Products Pty Limited. Roche
Roche Products
Products Pty
Pty Limited,
Limited, ABN
ABN 70
70 000
000 132
132 865,
865, Level
Level 8,
8, 30–34
30–34 Hickson
Hickson Road,
Road, Sydney
Sydney
NSW
NSW 2000.
2000. Medical
Medical Information:
Information: 1800
1800 233
233 950.
950. ®Registered
®
Registered Trademark
Trademark EMVTEC462
EMVTEC462 EC-AU-9128
EC-AU-9128 PreparedJan20
PreparedJan20Wednesday 19 February
Time Session Speaker Room
8:00am - 5:00pm Australia and New Zealand Lung For full workshop details please see
Cancer Nurses Forum (ANZ-LCNF) page 19
Nursing and Allied Health Workshop
9:00am - 4:00pm Faculty of Radiation Oncology For full workshop details please see
Lung Interest Cooperative (FROLIC) page 22
Workshop
9:30am - 5:00pm Australasian Lung Cancer Trials Room 101/102
Group (ALTG) Clinical Development
Workshop and Open SAC Meeting
10:00am - 4:00pm Lung Cancer Community Forum Room 103
NOW PBS LISTED
First-line treatment of Stage IV mNSCLC,
no EGFR/ALK/ROS1 genomic tumour
aberrations; WHO PS 0-1; further eligibility
criteria apply1
In PD-L1 Expressors and Non-Expressors 2
HELPING TO REDEFINE SURVIVAL
EXPECTATIONS FOR PATIENTS WITH mNSCLC*†2
*Non-Squamous: without EGFR/ALK genomic tumour aberrations, KEYTRUDA + pemetrexed + platinum
chemotherapy vs pemetrexed and platinum chemotherapy (HR=0.49; 95% CI, 0.38-0.64; PThursday 20 February
Time Session Speaker Room
7:00am - 8:00am Australasian Lung Cancer Trials Room 102
Group MAC Meeting
(ALTG members only)
8:00am - 9:00am Opening ceremony Prof Kwun Fong Room 105/106
Prof Tom John
9:00am - 10:00am Keynote presentations: Dr Marina Garassino Room 105/106
Prof Bin Jalaludin
Future directions for research in
Lung Cancer
Air quality and lung health
10:00am - 10:30am Morning tea (exhibition area)
Poster presentations (Room 104)
10:00am - 12:30pm Palliative care symposium Dr Jaclyn Yoong Room 103
Dr Michael Chapman
Dr Eswaran Waran
Prof David Currow
Prof Jane Phillips
10:00am - 12:30pm Plenary: Quality in Diagnostics and A/Prof Marie-Liesse Labat Room 105/106
Care: Dr Stephen Fox
‘Leaps & bounds’ in lung cancer in Dr Federico Cappuzzo
2020 A/Prof Gerry Hanna
A/Prof Gavin Wright
Dr Lara Edbrooke
Ms Mary Duffy
11:30am - 12:30pm Pfizer Symposium: Lung pathology in A/Prof Nick Pavlakis Room 109
the era of targeted therapies: ROS1 A/Prof Trishe Leong
testing in patients with advanced
non-small cell lung cancer
12:30pm - 1:30pm Lunch (exhibition area)
Poster presentations (Room 104)
12:30pm - 2:00pm Roche Symposium: Non-squamous Dr Federico Cuppuzzo Room 110
NSCLC: Selecting the right treatment
regimen for each patient
1:30pm - 3:00pm Symposium: Basic Science Dr Melvin Chin Room 102
Novel insights into the biology of Dr Clare Weeden
thoracic cancers Dr Jason Cain
Dr Mark Adams
Dr Sarah Best
Dr Marian Burr
14 Australian Lung Cancer Conference 2020 HandbookThursday program continued
Time Session Speaker Room
1:30pm - 3:30pm Plenary: Hope & Equity Prof Ben Solomon Room 105/106
Reinventing clinical trials A/Prof Nick Pavlakis
A/Prof Rob Stirling
A/Prof Gavin Wright
A/Prof Tom John
Renae Grundy
Lisa Briggs
Tom Wood
Melanie Lane
Lillian Leigh
1:30pm - 3:30pm Living with Thoracic Cancer and Prof Linda Denehy Room 109
Beyond: Dr Vin Calvaheri
Exercise in lung cancer Ms Jane Turner
Prof Rob Newton
Dr Jin-Soo Kim
Ms Nasreen Kadaan
1:30pm - 3:30pm Oral abstract presentations: Room 103
Screening and early detection
3:30pm - 4:00pm Afternoon Tea
4:00pm - 5:00pm Oral abstract presentations: Room 103
Epidemiology
4:00pm - 5:30pm Plenary: Living with Thoracic Cancer Ms Olivia Wong Room 105/106
and Beyond: Dr Catherine Holiday
Holistic long-term care A/Prof Joel Rhee
Dr Maria Ftanou
Dr Jaclyn Yoong
Ms Jacqueline Lesage
Dr Melissa Yang
4:00pm - 6:00pm ALTG clinical trial concepts Room 102
6:00pm - 7:30pm MSD Symposium: Redefining Prof Nir Peled Room 103
survival expectations for
lung cancer patients
7:00pm - 11:00pm ALCC 2020 Conference dinner & Lung Foundation Australia lung Room 109/110
cancer awards
15 Australian Lung Cancer Conference 2020 HandbookFriday 21 February
Time Session Speaker Room
7:00am - 9:00am ALTG Strategic planning meeting Room 102
(ALTG members only)
7:30am - 9:00am BMS: What is the future of Prof Michael Boyer Room 101
immunotherapy in NSCLC?
9:00am - 10:00am Keynote presentation: Prof Angela Tod Room 105/106
Prof Martin Phillips
Working Together: The power of a
multi-disciplinary approach in lung
cancer treatment & care
E-cigarettes: Good intentions gone
awry? The harmful consequences
10:00am - 10:30am Morning tea (exhibition area)
Poster presentations (Room 104)
10:30am - 12:30pm Oral abstract presentations: Room 102
Medical oncology
10:30am - 12:30pm Oral abstract presentations: Are we Room 103
delivering best practice treatment?
10:30am - 12:30pm Plenary: Quality in Diagnostics and Dr Vivienne Milch Room 105/106
Care: (Cancer Australia)
Lung cancer screening in Australia Dr Henry Marshall
A/Prof Paul Mitchell
Dr Brendan Adler
Dr Niranjan Karanth
Prof Nir Peled
10:30am - 12:30pm Symposium: Borderline inoperable Mr Julian Gooi Room 109
disease Dr Susan Harden
A/Prof Siven
Seevanayagam
Dr Fiona Hegi-Johnson
12:30pm - 1:30pm Lunch (exhibition area)
Poster presentations (Room 104)
16 Australian Lung Cancer Conference 2020 HandbookFriday program continued
Time Session Speaker Room
12:30pm - 2:00pm AstraZeneca Symposium: Putting Dr Marina Garassino Room 110
evidence into practice in locally
advanced and metastatic NSCLC
1:30pm - 3:00pm Oral abstract presentations: Room 102
Basic science
1:30pm - 3:30pm Oral abstract presentations: Room 103
Data-driven quality
1:30pm - 3:30pm Hope & Equity: Toward 2030 in lung Ms Lisa Briggs Room 105/106
cancer Mr Tom Wood
Prof David Ball
Prof Danielle Mazza
A/Prof Rob Stirling
A/Prof Angela Tod
1:30pm - 3:30pm Symposium: Mesothelioma Ms Dimitra Dubrow Room 109
(proudly sponsored by Maurice Prof Fraser Brims
Blackburn Lawyers) Dr Nicola Waddell
Prof Ken O'Byrne
A/Prof Gavin Wright
Prof Anna Nowak
A/Prof Gerry Hanna
3:30pm - 4:30pm Abstract Awards followed by Prof Kwun Fong Room 105/106
Closing Ceremony A/Prof Tom John
4:30pm - 4:45pm Afternoon tea
Thank you for joining us at ALCC 2020!
17 Australian Lung Cancer Conference 2020 HandbookWelcome
from the ANZ-LCNF Chair
As Chair of the Australia and New Zealand Lung Cancer Nurses Forum (ANZ-LCNF) I am very
pleased to extend my warmest welcome to everyone attending the Australian Lung Cancer
Conference 2020 in Melbourne.
The care provided by Lung Cancer Nurse Specialists improves clinical outcomes for patients
with lung cancer. As 2020 is the International Year of the Nurse, I am particularly excited we
are hosting the ANZ-LCNF workshop for nurses and allied health. This provides us with a great
opportunity for networking and collaborating with clinicians, research experts, and many health
professional members. It also gives us a unique occasion to shape how we can contribute to
Lung Foundation Australia’s current key advocacy efforts as outlined in the strategic document
‘Making Lung Cancer A Fair Fight: A Blueprint for Reform’.
It is my great pleasure to welcome Professor Angela Mary Tod as the international nurse
keynote speaker at this years’ workshop and conference.
I encourage all nurse an allied health attendees to enjoy all sessions provided in the ALCC
2020 program. Finally, I would like to echo the words of thanks extended by our conference
convenors, Prof Kwun Fong and A/Prof Tom John to the sponsors and exhibitors.
Mary Duffy, APN,
Lung Cancer Nurse Coordinator
18 Australian Lung Cancer Conference 2020 HandbookANZ-LCNF:
This event is proudly
sponsored by
Nursing and Allied Health
Workshop Program
Wednesday 19 February
Session 1: Diagnostics and Quality of Care
Chair: Ms Mary Duffy, APN
Time Session Speaker
7:45am for 8:00am Registration
start
8:00am - 8:10am Welcome Ms Mary Duffy APN, ANZ-LCNF
Chair
8:10am - 8:50am The impact of the specialist lung cancer Prof Angela Tod
nurse model on the health & wellbeing
outcomes of patients and families
8:50am - 9:20am Lung cancer optimal care pathways Prof Robert Thomas
9:20am - 9:50am 2020: A year in review of lung cancer Dr Surein Arulananda
9:50am - 10:30am Roche sponsored session: Holistic care Ms Helen Westman
of the patient on Tecentriq and Avastin Mr Michael Cooney
combination therapy
10:30am - 10:50am Morning tea
Session 2: Hope & Equity
Chair: Dr Vanessa Brunelli
10:50am - 11:15am The lived experience of lung cancer Mr Kane Morris
11:15am - 11:35am Telehealth to improve access and equity to Dr Vanessa Brunelli
cancer survivorship care
11:35am - 11:55am Equitable access to treatment in minority Mrs Carolyn Riordan
populations
11:55am - 12:15am Radiotherapeutic advances in the context of Dr Nikki Plumridge
cerebral metastases
12:15pm - 12:35pm Respiratory health and air quality Dr Alistair Miller
12:35pm - 1:05pm Lunch
19 Australian Lung Cancer Conference 2020 HandbookANZ-LCNF:
program continued
Session 3: Living with Thoracic Cancer and Beyond
Chair: Dr Lara Edbrooke
Time Session Speaker
1:10pm - 1:30pm Symptom management – challenges faced Ms Helen Westman
with new immune-oncology therapies
1:30pm - 1:50pm Cancer-related fatigue management Dr Elizabeth Pearson
1:50pm - 2:10pm Sarcopenia and cancer-related malnutrition Dr Nicole Kiss
2:10pm - 2:30pm Swallowing and voice outcomes after Dr Jacqui Frowen
radiotherapy for SCLC
2:30pm - 2:45pm Exercise across the lung cancer continuum Dr Lara Edbrooke
2:45pm - 3:05pm Afternoon tea
Session 4. Improving Nurse and Patient Outcomes in Lung Cancer
Chair: Dr Vanessa Brunelli
Time Session Speaker
3:10pm - 3:30pm Smoking cessation in Australia: Practical Ms Kelly Burton
strategies
3:30pm - 3:50pm Clinical debrief and good self mental health Ms Tessa Moriarty
3:50pm - 4:10pm ANZ-LCNF research and education update Dr Vanessa Brunelli
Ms Renae Grundy – PhD research
4:10pm Close Ms Mary Duffy APN, ANZ-LCNF
Chair
4:20pm - 5:00pm Drinks and networking
20 Australian Lung Cancer Conference 2020 HandbookTHE STANDARD OF CARE
FOR STAGE III
UNRESECTABLE NSCLC
that has not progressed post platinum-based CRT1–5
UNPRECEDENTED 3-YEAR
OVERALL SURVIVAL BENEFIT
in patients with Stage III unresectable
NSCLC whose disease has not progressed
post platinum-based CRT (vs placebo;
HR 0.69, 95% CI, 0.55-0.86).4-6
PLEASE CLICK HERE TO REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.
FURTHER INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA.
PBS Information: This product is not listed on the PBS.
CI: confidence interval; CRT: chemoradiation therapy; HR: hazard ratio; NSCLC: non-small cell lung cancer. References: 1. NCCN Guidelines. Non-small cell lung cancer v4.2019 (April 29 2019). Available at: www.nccn.org. 2. EviQ. Non small cell lung cancer
durvalumab. ID: 3512 v.1. Available at: https://www.eviq.org.au. 3. Antonia SJ, et al. N Engl J Med 2018; 379:2342-50. 4. IMFINZI Approved Product Information. 5. McCall NS, et al. Clin Cancer Res 2018;24:1271-6. 6. Gray JE, et al. ASCO 2019. Poster 8526.
IMFINZI® is a trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113.
www.astrazeneca.com.au. For Medical Information enquiries: 1800 805 342 or medinfo.australia@astrazeneca.com. To report an adverse event: 1800 805 342 or via
https://aereporting.astrazeneca.com. AU-7238. WL303014. Date of preparation: January 2020.
21 Australian Lung Cancer Conference 2020 HandbookFaculty of Radiation
This event is proudly sponsored by
Oncology Lung
Interest Cooperative
(FROLIC) Workshop Program
Wednesday 19 February
Co-Chairs: Dr Louis Lao and A/Prof Gerry Hanna
Wednesday 19 February
Time Presentation Speaker
9:00am - 9:15am Welcome A/Prof Gerry Hanna
Dr Louis Lao
9:15am - 10:15am Lung Cancer Radiotherapy: Where have we come Prof David Ball
from, where are we now and where are we going
to?
10:15am - 10:45am Morning tea
10:45am - 11:30am Radiotherapy in small cell lung cancer Dr Eric Hau
11:30am - 12:00pm What is the optimal systemic therapy regimen to Dr Marina Garassino
used in combination chemoradiation in NSCLC?
12:00pm - 12:30pm AstraZeneca Sponsored Session: Dr Marina Garassino
Considerations for CRT administration in stage III Prof David Ball
to limit post treatment complications?
12:30pm - 1:30pm Lunch
1:30pm - 1:45pm Motion management in NSCLC radiotherapy Dr Louise Nardone
1:45pm - 2:05pm Optimal dose and fractionation in the treatment Dr Louis Lao
of NSCLC with radiotherapy?
2:05pm - 2:20pm Proton therapy – Where did we get to? Dr Fiona Hegi-Johnson
2:20pm - 2:40pm Radiotherapy in thymoma and mesothelioma A/Prof Gerry Hanna
2:40pm - 3:10pm Afternoon Tea
3:10pm - 3:55pm Management of oligometastatic disease in NSCLC: A/Prof Shankar Siva
Who, what, where, why and when?
3:55pm - 4:00pm Session close A/Prof Gerry Hanna
Dr Louis Lao
22 Australian Lung Cancer Conference 2020 HandbookAustralasian Lung Cancer
Trials Group (ALTG)
The Australasian Lung Cancer Trials Group (ALTG) is a member-based organisation
representing respiratory physicians, medical oncologists, radiation oncologists, palliative
care specialists, cardiothoracic surgeons, scientists, nurses, clinical trial professionals and
consumer representatives.
ALTG objectives are: Benefits of ALTG membership include:
• To facilitate participation in the • A network of multidisciplinary professionals
development, conduct, evaluation, across Australia and New Zealand who are
reporting of clinical trials in lung cancer and passionate about research for lung and thoracic
mesothelioma. cancers, such as clinicians, nursing, allied health,
• To promote the use of clinical trials consumer and industry representatives.
in evaluating new treatments and • Support for developing your research ideas
management approaches for lung cancer for investigator-initiated studies from
and mesothelioma. concept to protocol and study conduct.
• To contribute to the translation of clinical • Regular member meetings to develop
trial findings into clinical practice. research ideas and hear speakers on cutting-
edge research topics.
Join ALTG today • Educational opportunities including the ALTG
Preceptorship in Lung Cancer and the ALTG
Visit altg.com.au Annual Scientific Meeting.
• Financial support to attend ALTG meetings in
the form of travel grants.Abstracts: Poster Listing
Dr Ayman Alidina - Immunotherapy in mesothelioma: A/Prof Chee Lee - A phase 2 trial of Durvalumab (MEDI4736)
Case studies from a regional cancer centre and Tremelimumab with chemotherapy in metastatic EGFR
mutant non-squamous non-small cell lung cancer following
Dr Prachi Bhave - Optimising pathways to maximal
progression on EGFR Tyrosine Kinase Inhibitors (ILLUMINATE)
pathological diagnosis of metastatic non-small cell
lung cancer Dr Jennifer Lim - Predictive biomarkers for platinum
sensitivity in advanced non-small cell lung cancer –
Dr Charlotte Chen - Surgical treatment of non-small
study schema
cell lung cancer in octogenarians: A single centre
retrospective study Prof Linda Mileshkin - A randomised phase 3 trial
of early referral to palliative care for patients with
Mrs Kirsten J Duggan - Lung cancer extent of disease,
advanced thoracic malignancies (PEARL)
treatment patterns and survival - The effect of
culturally and linguistically diverse status in south Dr Cienne Morton - Survival outcomes and prognostic
western Sydney factors in unresectable Stage III NSCLC treated with
concurrent chemoradiotherapy. A single institution audit
Dr James Farag - Surgical management of pulmonary
from the Princess Alexandra Hospital, Brisbane
artery angiomatoid fibrous histiosarcoma
Dr Sara Pacella - Prognostic value of restaging 18F- FDG
Ms Tracey Guan - Lung cancer in patients aged 65+
PET/CT in patients with small cell lung cancer
years: Who do we treat and how do we treat them?
Ms Brielle Parris - Molecular testing of small
Dr Harshan Jeyakumar - Improving regional lung cancer
bronchoscopy specimens using NanoString technology
optimal care pathway compliance through a rapid-access
respiratory clinic Miss Sobasha Perera - Surveillance, patterns of
recurrence and survivorship in early stage non-small cell
lung cancer patients
For more
information,
visit us at
Booth 10
© 2020 Bristol-Myers Squibb. OPDIVO® is a registered trademark of Bristol-Myers Squibb Company.
BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322,
4 Nexus Court, Mulgrave, VIC 3170. 1506AU2000940-01. Date of preparation: February 2020. BRMSCH1514.
24 Australian Lung Cancer Conference 2020 HandbookAbstracts: Poster Listing continued
Miss Sophie Pickles - Investigating the role of Dr Simon Slader - The concordance between clinical
mitochondria-targeted H2S donors for the treatment of and pathological TNM stage in non-small cell lung
NSCLC cancer, a retrospective audit
Dr Kuan Pin Lim - Differences in lung cancer stage Ms Catherine Smith - Demographics of patients with
distribution in private and public hospital settings lung cancer diagnosed in the upper South Island of New
Zealand: A ten-year audit
Miss Aleksandra Rajapakse, Dr Connor O’Leary &
Mr Ken O’Byrne - Autoimmune inner ear disease in an Dr Ashley Tan - Nobody expected the Spanish
advanced lung cancer patient treated with nivolumab Inquisition! Lung cancers found in unexpected ways
Dr Nicole Rankin - Implementation of lung cancer Dr Ashley Tan - Early stage lung cancers detected in
multidisciplinary care: A rapid review of evidence- asymptomatic patients in an Australian private hospital
practice gaps setting
Ms Korinna Selga - Patient reported outcome Dr Harshil Trivedi - Multidisciplinary team patterns
measures in a Western Australian pilot group of lung of care for Stage III NSCLC and evaluation of guideline
cancer patients: Implementation of the continuous adherence – single-centre analysis
improvement in care - Cancer (CIC Cancer) Project
Dr Hannah Wade - Surgical rates in Stage I NSCLC: Audit
Dr Clare Senko - Cancer-testis antigens (CTAs), PD- of multidisciplinary team practice
L1 and overall survival in surgical non-small cell lung
Dr Veronica Wong & Dr Ashley Heyworth - FDG
cancer: Potential immune mechanisms
PET/CT for the staging of mediastinal lymph node
Dr Prajwol Shrestha - A rare case of bullous pemphigoid involvement in lung cancer
associated with squamous cell carcinoma of lung showing
remarkable response to carboplatin based chemotherapy
in elderly: Case report and literature review
In the era of molecular targeted therapies1
Unlock the potential of
the only TKI approved for
ROS1-positive NSCLC2-5
At diagnosis, request…
EGFR ALK ROS 1
…testing
Recommended by ASCO, ESMO and NCCN6-9
PBS information: Authority required for the treatment of ALK+ & ROS1+ advanced NSCLC.
Refer to the PBS Schedule for full authority information.
PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING.
PRODUCT INFORMATION IS AVAILABLE FROM THE TRADE DISPLAY.
References: 1. Nicholson AG et al. Sample Acquisition, Processing, and General Diagnostic Procedures. In Tsao MS, et al. IASLC Atlas Of
ALK and ROS1 Testing in Lung Cancer. Second Edition. 2016. International Association for the Study of Lung Cancer, Aurora, CO, USA.
2. XALKORI Approved Product Information. 3. ALECENSA® (alectinib) Approved Product Information. 4. ZYKADIA® (ceritinib) Approved
Product Information. 5. Shaw AT, et al. N Engl J Med. 2014; 371:1963-71. 6. National Comprehensive Cancer Network (NCCN). Non-small ®
Registered trademark.
Cell Lung Cancer. Version 3. 2019 January 18, 2019. Available at www.nccn.org. Accessed February 2019. 7. Kalemkerian GP, et al. J Clin Pfizer Australia Pty Limited, Sydney, Australia.
Oncol. 2018; 36 (9): 911-919. 8. Planchard D, et al. on behalf of the ESMO Guidelines Committee. Ann Oncol. 2018; 29 (Supplement_4): Pfizer Medical Information: 1800 675 229.
iv192-iv237. 9. Pavlakis, N et al . Pathology. 2019; 51(7):673-680 PFE1247. PP-XLK-AUS-0264. February 2020.
25 Australian Lung Cancer Conference 2020 Handbook
PFE1247_Xalkori_186x153.5mm_Ad_R3.indd 1 12/2/20 3:43 pmAbstracts Oral Presentations
Standard Oral
Rapid Fire
New Investigator
Dr Afaf Abed - Genomic HLA as a predictive marker for overall survival Prof Michael Macmanus - What proportion of patients commence
in non-small cell lung cancer patients post immunotherapy but fail to complete curative-intent chemoradiotherapy for non-small
Dr Surein Arulananda - BCL-XL inhibition in combination with cisplatin cell lung cancer?
is effective in malignant pleural mesothelioma due to its dependency Dr Lin Mo - The international lung screen trial: Results from three
on the BCL-XL pro-survival protein Australian sites
Prof Fraser Brims - Targeted lung cancer screening in Australia: is there Ms Kirsten Mooney - Harnessing innovation to improve outcomes
a need to account for asbestos exposure? for lung cancer patients: Proof of concept for prehabilitation within a
Dr Kim-lin Chiew - A future role for quality indicators in lung cancer tertiary hospital.
multidisciplinary teams Mr Preston Ngo - Real-world treatment patterns for lung cancer:
Miss Vrushali Chimankar - Can genomic sequencing on mouse model Systemic therapy utilisation and factors relating to treatment in
of lung cancer help us to understand the genetics of human lung Australia
cancer? Prof Nir Peled - Pembrolizumab plus Chemotherapy for advanced
Dr Venessa Chin - Single-cell transcriptomics and proteomics to assess NSCLC without tumor PD-L1 expression: Pooled analysis of KEYNOTE-
response to immunotherapy in real-time 021G, KEYNOTE-189 and KEYNOTE-407
Ms Vivienne Chipman - Building health literacy among culturally and Dr Jonathan Pham - Excess mortality in elderly patients diagnosed
linguistically diverse Australians affected by lung cancer with advanced lung cancer is related to under-prescribing of active
treatments, after controlling for confounders
Dr Laura Croft - A first in class DNA repair inhibitor for the treatment of
lung cancer Dr Hema Ramarmuty - Convex probe EBUS bronchoscopy guided
placement of fiducial marker in oligo-metastatic mediastinal lymph
Dr Paul Dawkins - Development of national quality performance
nodes for cyberKnife stereotactic body radiotherapy – Safety and
indicators for lung cancer in New Zealand
feasibility
Tracey Guan - QOOL-Dash: converting data to accessible information
Dr Nicole Rankin - The potential for implementation of LDCT lung
for real-time monitoring of lung cancer outcomes for patients reviewed
cancer screening in the Australian setting: outcomes of an evidence
at MDT in Queensland
check review
Dr Pei Ding - Plasma ctDNA T790M mutation load predicts response
Miss Katherine Bahar Sahin - Evaluation of AURKA inhibition as a
to second line Osimertinib in patients with advanced epidermal growth
novel strategy to improve EGFR-mutant tumour response to tyrosine
factor receptor mutant non-small cell lung cancer: An Australian
kinase inhibitors
multicentre retrospective study
Miss Priyanka Sahu - Novel mouse model for investigating the
Dr Lara Edbrooke - Physical activity levels are low in people with
pathogenesis of early stage squamous cell lung carcinoma
inoperable lung cancer
A/Prof Jasotha Sanmugarajah - 30-day mortality following
Dr Samantha Ennis - Extent of emphysema in low dose CT scans
intravenous systemic therapy for non-small cell lung cancer patients
performed for lung cancer screening in an Australian cohort
in Queensland
Dr Fanny Franchini - Patterns of care in never-smokers versus smokers
Dr Matthew Soeberg - Lung cancer and its association with asbestosis
in the treatment of lung cancer
mortality: What can we find out from Australia’s cause of death data
Dr Marina Chiara Garassino - PD-L1 expression, patterns of progression
Dr Emily Stone - ILST Australia: Impact of recruitment strategy
and patient-reported outcomes with Durvalumab plus Platinum-
on eligibility rates for LDCT lung cancer screening at baseline in an
Etoposide in extensive-stage small-cell lung cancer: Results from the
Australian centre
randomised, controlled, open label phase 3 CASPIAN trial
Dr Emily Stone - ILST (International Lung Screen Trial) Australia:
Dr Daryn Goodwin - The use of next generation sequencing in the
Baseline results at an Australian trial centre for low dose CT screening
characterisation of multiple primary lung cancers
for lung cancer
Dr Daniel Gough - STAT3 deletion increases metastatic small cell lung
Dr Amila Suraweera - Defining a novel DNA repair protein as an anti-
cancer
cancer therapeutic target in non-small cell lung cancer
Dr Susan Harden - Utilising a national clinical quality registry to drive
Dr Kate Sutherland - Harnessing natural killer immunity in metastatic
improvement in lung cancer outcomes: Radiation oncology examples
small cell lung cancer
from the UK National Lung Cancer Audit
Ms Louise Underhill - “Hanging on the telephone” – measuring the
Prof Rina Hui - KEYNOTE-024 3-year survival update: Pembrolizumab
impact of a telephone-based specialist lung cancer nursing service
vs Platinum-Based Chemotherapy for advanced non-small cell lung
cancer Dr Stephen Wade - Estimated smoking rates over the next 50 years
in Australia
Ms Elena Jensen-Marini - Exploring patient reported quality of life in
lung cancer patients: A qualitative study Dr Marianne Weber - Estimated risk for lung cancer incidence and
mortality related to tobacco smoking among 229,028 Australians
A/Prof Tom John - Osimertinib vs comparator EGFR-TKI as first-line
treatment for EGFRm advanced non-small cell lung cancer (FLAURA): Tracey Guan - Lung cancer clinical practice indicators for Queensland:
Final overall survival analysis A work in progress
Dr Kuan Pin Lim - Comparing recruitment strategies in lung cancer A/Prof Jasotha Sanmugarajah - Timely lung cancer care is influenced
screening: GP-based mail-outs or population-based mail-outs? by stage at diagnosis, a population-wide study from Queensland
Dr Patrick MaClean - Influence of the time interval from diagnosis to Mrs Hui You - Patterns of treatment and survival for people with small
treatment on survival for early-stage non-small cell lung cancer cell lung cancer in NSW
26 Australian Lung Cancer Conference 2020 HandbookHow can you
support us?
Invest in the Future
Scientific breakthroughs can take years to accomplish. Invest in a future free from
lung disease by leaving a bequest or gift as part of your Will. Leaving a bequest is
a way of ensuring you can continue to support the causes that are special to you,
even after you’re gone. Equally, talking with your family about a Gift in Memoriam
celebrates your life and gives hope to others.
Help Find a Cure
Your donation can help us understand the causes and future treatments of
lung disease. Regular giving is our most precious source of revenue. It gives us
certainty and continuity in an unpredictable funding environment and provides an
independent source of funding. A donation of $5.00 per week goes a long way. Put
simply regular donations allow great science to flourish.
Get Involved
More than ever, Australians are aware of the need to increase research funding to
fight lung disease and give hope to their fellow Australians. Share your story, become
a Lung Foundation Australia Ambassador or join workplace giving. There are many
ways you can support Lung Foundation Australia and make a difference.
Philanthropy and Partnerships
Lung Foundation Australia is proud to partner with philanthropists, companies,
trusts and foundations to raise vital funds for lung disease research. We focus
on forming personalised connections with donors and supporters to achieve our
mission. We are outcomes focused and ensure your investment is tracked against
measurable goals. As with all our support, we keep you up-to-date on progress.
This is our promise.
Community Fundraising
Celebrate hope and support your loved one, friend or work colleague by doing
something you love. Join our team, take part in a fun run, cycle or hold an event.You can also read
